Eis Eczacibasi Ilac, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.s. · BIST:ECILC
Eis Eczacibasi Ilac, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.s — Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar — Shareholder Meeting (April 2017)
27 slides from Eis Eczacibasi Ilac, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.s's shareholder meeting presentation, Apr 13, 2017
Slide 1: Eczacibasi
Eczacibasi
Slide 2: Table of Contents
TABLE OF CONTENTS General Information Activity Information Consolidated Healthcare Consumption Real Estate Development Future Strategies BIST Indicators
Slide 3: General Information
ECZACIBAŞI İLAÇ, SINAİ VE FİNANSAL YATIRIMLAR General Information Shareholding Structure Affiliates and Partnerships Existing Consolidated Structure
Slide 4: Shareholding Structure
SHAREHOLDING STRUCTURE AMOUNT SHAREHOLDING NAME OF THE SHAREHOLDER (TRY) RATIO (%) ECZACIBAŞI HOLDİNG A.Ş. 346,845,460 50.62 ECZACIBAŞI YATIRIM HOLDİNG ORT. A.Ş. 201,116,812 29.35 PUBLIC SHAREHOLDERS (Out-of-Group Shares) 137,297,727 20.04 TOTAL 685,260,000 100.00
Slide 5: Affiliates and Partnerships
AFFILIATES AND PARTNERSHIPS NOMINAL SHAREHOLDING CAPITAL SHAREHOLDING RATIO (%) (TRY) AMOUNT (TRY) SUBSIDIARIES EİP Eczacıbaşı İlaç Pazarlama A.Ş. 99.9 56,055,120 56,100,000 Eczacıbaşı Gayrimenkul Geliştirme ve Yatırım A.Ş. 99.5 2,487,353 2,500,000 Eczacıbaşı İlaç Ticaret A.Ş. 94.7 47,350 50,000 JOI
Slide 6: Existing Consolidated Structure
EXISTING CONSOLIDATED STRUCTURE ECILC Healthcare Consumption Real Estate Other Development • Ecz. İlaç Pazarlama 99.9% • Girişim Pazarlama 48.1% • Ecz. Holding 37.3% • Kanyon Office 100.0% • Ecz. İlaç Cyprus Ltd. 99.9% • Eczacıbaşı Hijyen 48.1% • Ecz. Dış Tic. 26.4% • Ecz. Gayrimenkul 99.5% • Ecz. İ
Slide 7: Activity Information
ECZACIBAŞI İLAÇ, SINAİ VE FİNANSAL YATIRIMLAR Activity Information Consolidated Healthcare Consumption Real Estate Development
Slide 8: Consolidated Indicators for 2015-2016
CONSOLIDATED INDICATORS FOR 2015- 2016 (TRY MILLION) 2015 2016 ∆ (%) Consolidated Total Assets: 3,370 3,993 18.5 Consolidated Total Equity: 2,740 3,245 18.4
Slide 9: Consolidated Indicators for 2015-2016
CONSOLIDATED INDICATORS FOR 2015 - 2016 (TRY MILLION) 2015 1.413 1.500 2016 1.171 184,8 200 1.000 150 100 67,6 500 50 0 0 CONSOLIDATED CONSOLIDATED NET SALES PROFIT FOR THE PERIOD
Slide 10: Healthcare - Material Developments in the Sector
CONSOLIDATED SEGMENT DEVELOPMENTS FOR 2016 - HEALTHCARE - MATERIAL DEVELOPMENTS IN THE SECTOR A relative improvement was realized by updating the fixed Euro rate, on which the drug prices are based pursuant to the drug pricing system of the Ministry of Health, at 70% of the average of 2016 and the
Slide 11: Healthcare - Eczacıbaşı İlaç Pazarlama (EİP)
CONSOLIDATED SEGMENT DEVELOPMENTS FOR 2016 - HEALTHCARE - DEVELOPMENTS IN ACTIVITIES Eczacıbaşı İlaç Pazarlama (EİP) As a result of the license agreement concluded between EİP and Zydus Cadila, the Turkish license rights were obtained for 4 products in biosimilars area and it is planned that the f
Slide 12: Healthcare - Eczacıbaşı-Monrol
CONSOLIDATED SEGMENT DEVELOPMENTS FOR 2016 - HEALTHCARE - DEVELOPMENTS IN ACTIVITIES Nuclear Medicine Eczacıbaşı - Monrol Within the scope of its strategic targets as focusing on molecular technology and radiopharmaceuticals production, being the main field of activity of Eczacıbaşı- Monrol, incre
Slide 13: Healthcare - Eczacıbaşı-Monrol
CONSOLIDATED SEGMENT DEVELOPMENTS FOR 2016 - HEALTHCARE - DEVELOPMENTS IN ACTIVITIES Nuclear Medicine Eczacıbaşı - Monrol In 2016, the company continued its radiopharmaceuticals production activities with its four domestic and seven foreign production facilities. The company maintained its reg
Slide 14: Healthcare - Eczacıbaşı Ortak Sağlık ve Güvenlik
CONSOLIDATED SEGMENT DEVELOPMENTS FOR 2016 - HEALTHCARE - DEVELOPMENTS IN ACTIVITIES Healthcare Services Eczacıbaşı Ortak Sağlık ve Güvenlik Birimi Established in July 2013 with 100% participation of Eczacıbaşı Sağlık Hizmetleri within the scope of the latest legislative regulations regarding th
Slide 15: Healthcare - Eczacıbaşı-Baxter / Eczacıbaşı-Shire
CONSOLIDATED SEGMENT DEVELOPMENTS FOR 2016 - HEALTHCARE - DEVELOPMENTS IN ACTIVITIES Eczacıbaşı - Baxter / Eczacıbaşı - Shire As a result of Baxter Group's division of Medical Products and Biotechnological Products lines of business in two as Baxter and Baxalta around the world; so as to be carry
Slide 16: Consumption - Developments in the Sector
CONSOLIDATED SEGMENT DEVELOPMENTS FOR 2016 - CONSUMPTION - DEVELOPMENTS IN THE SECTOR In 2016, the following growths were achieved based on TRY: Fast Moving Consumer Products market: 15%* Personal Care market: 9% Body Care sub-market: 11% Hair Care sub-market: 7% Paper Products sub-marke
Slide 17: Consumption - Eczacıbaşı Girişim Pazarlama
CONSOLIDATED SEGMENT DEVELOPMENTS FOR 2016 - CONSUMPTION - DEVELOPMENTS IN ACTIVITIES Eczacıbaşı Girişim Pazarlama Eczacıbaşı Hijyen Ürünleri strengthen its market leadership, achieved last year in the wet baby towel category, in 2016 by increasing its market share. Focusing on the baby care cat
Slide 18: Consumption - Eczacıbaşı Girişim Pazarlama
CONSOLIDATED SEGMENT DEVELOPMENTS FOR 2016 - CONSUMPTION - DEVELOPMENTS IN ACTIVITIES Eczacıbaşı Girişim Pazarlama Having completed its organization in 2013 with a customer- oriented service concept, Eczacıbaşı Profesyonel demerged from Girişim Pazarlama as of the end of 2015 and it currently cont
Slide 19: Real Estate Development - Kanyon
CONSOLIDATED SEGMENT DEVELOPMENTS FOR 2016 - REAL ESTATE DEVELOPMENT - KANYON Kanyon, whose office block is 100% held by EİS and whose shopping center is 50% held by EİS, continued being a wellness and shopping center with its creative events and new projects. Considering also the increase in co
Slide 20: Real Estate Development - Ormanada Project
CONSOLIDATED SEGMENT DEVELOPMENTS FOR 2016 - REAL ESTATE DEVELOPMENT - ORMANADA PROJECT The 50% of the project, completed at the end of 2014, is held by EİS. The project includes 273 residence and the transfer of 86% of the project was completed. The construction works were completed as of the
Slide 21: Future Strategies
ECZACIBAŞI İLAÇ, SINAİ VE FİNANSAL YATIRIMLAR Future Strategies
Slide 22: Future Strategies - Healthcare
FUTURE STRATEGIES HEALTHCARE In the healthcare sector, to open new lines of business, and to utilize strategic cooperation opportunities; In the existing lines of business, to accelerate and deepen the organic growth with new products, differentiated services, digitalization and business model i
Slide 23: Future Strategies - Consumption and Real Estate
FUTURE STRATEGIES CONSUMPTION In the Fast Moving Consumer Products sector, to continue our leadership in our existing fields of activity; In the "fast moving consumer products" market, to enter into the other categories particularly the new "personal care products" creating synergy; In the pro
Slide 24: BIST Indicators
ECZACIBAŞI İLAÇ, SINAİ VE FİNANSAL YATIRIMLAR BIST Indicators
Slide 25: ECILC - BIST50, 1 January 2016 - 31 March 2017
ECILC - BIST50 1st January 2016 - 31st March 2017 (15 months)
Slide 26: ECILC - BIST100, 1 January 2016 - 31 March 2017
ECILC - BIST100 1st January 2016 - 31st March 2017 (15 months)
Slide 27: Thank You
THANK YOU
Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar — Shareholder Meeting (April 2017) on 6ix